Alpha-Glucosidase Inhibitors in Aging and Aging-Related Diseases: Clinical Applications and Relevant Mechanisms

Ling Zhong, Litao Yang, Jamil Syed, Yuwei Zhang, Yanqing Tian, Dingwen ZhangAging 2025 · DOI

This review paper, published in Aging and Disease, explores the potential of repurposing a common class of Type 2 Diabetes (T2DM) medications—Alpha-Glucosidase Inhibitors (AGIs)—as "geroprotectors" to slow the biological aging process and combat age-related chronic diseases.

TL;DR

Common antidiabetic drugs like acarbose do more than just manage blood sugar; they appear to extend lifespan and protect against cardiovascular disease, cancer, and neurodegeneration. By slowing carbohydrate absorption and modulating the gut microbiome, AGIs trigger systemic anti-aging effects that could shift the paradigm from treating individual diseases to targeting the aging process itself.

What Problem Does This Paper Address?

The "geroscience hypothesis" suggests that since aging is the primary risk factor for most chronic diseases (heart disease, cancer, Alzheimer’s), we should target the underlying biological mechanisms of aging rather than treating each condition in isolation.

While "senotherapeutics" (drugs that kill or suppress senescent cells) are a hot area of research, they are relatively new. This paper addresses the gap in summarizing the evidence for Alpha-Glucosidase Inhibitors (AGIs)—drugs with decades of safety data—as viable candidates for systemic anti-aging therapy. The authors synthesize clinical and preclinical data to explain how these drugs influence longevity beyond simple glycemic control.

Methods

As a comprehensive review, the authors conducted a systematic search of the PubMed database for English-language studies published through October 2024. They synthesized data from:

  • Clinical Trials: Analyzing outcomes from major studies like the STOP-NIDDM and ACE trials.
  • Preclinical Models: Reviewing lifespan and disease-progression data from rodent models (e.g., HET3 mice, 3xTg Alzheimer’s models).
  • Mechanistic Studies: Mapping out the molecular pathways (oxidative stress, nutrient sensing, and gut microbiota) affected by AGIs.

Datasets

The paper reviews a vast array of existing data rather than introducing a new dataset. Key sources include:

  • The Interventions Testing Program (ITP): A multi-institutional study funded by the NIA that provided the definitive data on acarbose-mediated lifespan extension in mice.
  • Large-scale Cohort Studies: Data from tens of thousands of patients in Taiwan and China regarding cancer risk and cardiovascular outcomes (e.g., the Beijing Community Diabetes Study 24).
  • Clinical Indices: Metrics such as Carotid Intima-Media Thickness (CIMT), HbA1c levels, and Major Adverse Cardiovascular Events (MACE).

Key Insights and Ideas

  • The "Male Advantage" in Longevity: One of the most striking findings in rodent studies is that acarbose extends lifespan significantly more in males (up to 22% increase in median lifespan) than in females (only ~5%). This suggests a complex interaction with sex hormones that requires further human investigation.
  • The Gut as a Bioreactor: AGIs work by preventing sugar absorption in the small intestine. This sends undigested starch to the large intestine, where it acts as a prebiotic. This shifts the microbiome toward beneficial species (Bifidobacterium, Lactobacillus) and increases the production of Short-Chain Fatty Acids (SCFAs), which have systemic anti-inflammatory effects.
  • Beyond Blood Sugar: The anti-aging effects are "glycemic-independent." Even in non-diabetic models, AGIs reduce oxidative stress and modulate nutrient-sensing pathways like mTORC1 and AMPK, which are the "master switches" of cellular aging.
  • Neuroprotection: Emerging evidence suggests AGIs can mitigate cognitive decline and reduce amyloid-β aggregation in Alzheimer's models, likely by reducing systemic inflammation and improving brain energy metabolism.

Key Results

  • Lifespan: In the NIA’s ITP study, acarbose increased the median lifespan of male mice by 22% and maximum lifespan by 12%.
  • Cardiovascular Health: Clinical data showed acarbose could reduce the risk of myocardial infarction (heart attack) by up to 91% and hypertension by 34% in patients with impaired glucose tolerance.
  • Cancer Prevention: Population-based studies indicated a significant correlation between AGI use and reduced risks of lung, gastric, hepatic, and colorectal cancers.
  • Inflammation: AGIs were shown to shift macrophage polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype.

Limitations and Future Work

The authors highlight several hurdles before AGIs can be prescribed as "longevity pills":

  1. Gastrointestinal Side Effects: The primary drawback of AGIs (flatulence, diarrhea) leads to lower patient compliance, which might be a barrier for healthy individuals.
  2. Human Longevity Data: While the rodent data is robust, there are no long-term prospective trials specifically measuring lifespan extension in healthy humans.
  3. Sex Differences: The mechanism behind why males benefit more than females remains poorly understood and needs to be addressed in human clinical trial design.
  4. Combination Therapies: The authors suggest that combining AGIs with other geroprotectors (like Rapamycin) could yield synergistic effects, but this area is still in its infancy.

Summary updated

Abstract

Aging is a complex and universal process marked by gradual functional declines at the cellular and tissue levels, often leading to a range of aging-related diseases such as diabetes, cardiovascular diseases, and cancer. Delaying the aging process can help prevent, slow down, and alleviate the severity of these various conditions, enhancing overall health and well-being. Alpha-glucosidase inhibitors (AGIs) are a class of widely used antidiabetic drugs that inhibit alpha-glucosidase in the small intestinal mucosa, delaying carbohydrate absorption and reducing postprandial hyperglycemia. Beyond their roles in diabetes treatment, AGIs have shown potential in extending lifespan and effectively treating aging-related diseases by modulating oxidative stress, gut microbiota, inflammatory responses, and nutrient-sensing pathways. This review summarizes recent advancements in the application of AGIs for preventing and treating aging and aging-related diseases, with a focus on their mechanisms and roles in these processes.
BibTeX
@inproceedings{zhong2025alpha,
  author = {Ling Zhong and Litao Yang and Jamil Syed and Yuwei Zhang and Yanqing Tian and Dingwen Zhang},
  title = {{Alpha-Glucosidase Inhibitors in Aging and Aging-Related Diseases: Clinical Applications and Relevant Mechanisms}},
  booktitle = {Aging},
  year = {2025},
  doi = {10.14336/ad.2024.1477},
}
Figure